Results 111 to 120 of about 3,523 (219)

Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature [PDF]

, 2020
Eveline Hofmann, Daniel Sidler, Suzan Dahdal, Pascal Bittel, Franziska Suter‐Riniker, Oriol Manuel, Laura N. Walti, Cédric Hirzel   +7 more
openalex   +1 more source

The direct and indirect consequences of cytomegalovirus infection and potential benefits of vaccination [PDF]

, 2020
Active infection with cytomegalovirus (CMV) occurs in patients who are immunocompromised and may produce the high viral loads required to cause end-organ disease.
Griffiths, P
core  

P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

, 2022
David Beauvais, M. Sourisseau, Hélène Behal, S. Alfandari, Nicolas Simon, Emilie Faure, Ibrahim Yakoub‐Agha   +6 more
openalex   +1 more source

Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant [PDF]

, 2020
Terri Lynn Shigle, Victoria Handy, Roy F. Chemaly   +2 more
openalex   +1 more source

Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy

Infection and Drug Resistance, 2019
Umberto Restelli,1,2 Davide Croce,1,2 Valeria Pacelli,1 Fabio Ciceri,3,4 Corrado Girmenia51Center for Health Economics, Social and Health Care Management, LIUC - Università Cattaneo, Castellanza, VA, Italy; 2School of Public Health, Faculty of ...
Restelli U, Croce D, Pacelli V, Ciceri F, Girmenia C   +4 more
doaj  

Letermovir [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients

Drug Design, Development and Therapy
Raymund R Razonable1,2 1Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN, USA; 2William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USACorrespondence ...
Razonable RR
doaj  

Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis

Turkish Journal of Hematology
Objective: Cytomegalovirus (CMV) reactivation is a life-threatening complication after allogeneic hematopoietic stem cell transplantation (HSCT).
Martyna Wlodarczyk, Agata Wieczorkiewicz-Kabut, Krzysztof Białas, Anna Koclęga, Izabela Noster, Patrycja Zielińska, Grzegorz Helbig   +6 more
doaj   +1 more source

Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients: An Update

Viruses
Despite the significant progress made, CMV infection is one of the most frequent infectious complications in transplant recipients. CMV infections that become refractory or resistant (R/R) to the available antiviral drugs constitute a clinical challenge ...
Léna Royston, Genovefa A. Papanicolaou, Dionysios Neofytos   +2 more
doaj   +1 more source

Multicenter Analysis of Valganciclovir Prophylaxis in Pediatric Solid Organ Transplant Recipients [PDF]

BACKGROUND: Valganciclovir is the only approved antiviral for cytomegalovirus (CMV) prevention in pediatric solid organ transplantation (SOT). Additional approaches may be needed to improve outcomes.
Ardura, Monica I, Bacon, Samantha, Blum, Samantha, Bocchini, Claire E, Boguniewicz, Juri, Danziger-Isakov, Lara, Demirhan, Salih, Ferrolino, Jose, Foca, Marc, Heald-Sargent, Taylor, Herold, Betsy C, Joseph, Tuhina, Maron, Gabriela M, Muller, William J, Munoz, Flor M, Sharma, Tanvi S, Sherman, Gilad, Smith, Jodi, Su, Yin, Valencia Deray, Kristen G   +19 more
core   +2 more sources